NCT02559180View on ClinicalTrials.gov

Treatment of Diabetic Macular Edema With Aflibercept in Subjects Previously Treated With Ranibizumab or Bevacizumab

PHASE4CompletedINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

October 31, 2015

Primary Completion Date

December 31, 2020

Study Completion Date

December 31, 2020

Conditions
Diabetic RetinopathyMacular Edema
Interventions
DRUG

aflibercept

aflibercept 2mg given intravitreally every month until resolution of fluid in retina and then continued every 2 months for a total of 24 months of treatment

Trial Locations (1)

44195

Cole Eye Institute, Cleveland Clinic, Cleveland

All Listed Sponsors
collaborator

Regeneron Pharmaceuticals

INDUSTRY

lead

Rishi Singh

OTHER

NCT02559180 - Treatment of Diabetic Macular Edema With Aflibercept in Subjects Previously Treated With Ranibizumab or Bevacizumab | Biotech Hunter | Biotech Hunter